Effect of Chloroquine on Type 2 Inflammatory Response in MC903-Induced Atopic Dermatitis Mice
DOI: https://doi.org/10.2147/ccid.s440308
2024-05-15
Clinical Cosmetic and Investigational Dermatology
Abstract:Mingjing Wei, &ast Huixue Yang, &ast Zhengchao Shao, Haoyue Wan, Yiheng Wang, Wenqi Chen Department of Dermatology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wenqi Chen, Department of dermatology, Nanjing First Hospital, Nanjing Medical University, Changle Road 68, Nanjing, Jiangsu, 210000, People's Republic of China, Tel +8615261008432, Email Introduction: Atopic dermatitis (AD) is a chronic, non-infectious inflammatory dermatosis. Chloroquine (CQ) has long been proven to possess anti-inflammatory properties. Objective: This paper aims to investigate the impact of CQ on type 2 inflammatory response in MC903-induced AD mice. Methods: An AD mouse model was established via MC903 induction. After CQ treatment, AD mice were intraperitoneally injected with polyinosinic: polycyclic acid [poly (I:C)] or Nigericin. Dermatitis severity was scored, and the thickness of the left ear was measured. The pathological changes in mouse skin tissues were observed by H&E staining. The number of mast cells was counted via TB staining. The content of peripheral blood T-helper 2 (Th2) cells and levels of immunoglobulin E (IgE), thymic stromal-derived lymphopoietin (TSLP), interleukin (IL)-4, IL-13, interferon (IFN)-γ, IL-1β, and IL-18 were assessed by flow cytometry and ELISA. The levels of toll-like receptor 3 (TLR3), NLRP3, ASC, and cleaved caspase-1 proteins in skin tissues were determined by Western blot. Results: CQ treatment abated dermatitis severity and left ear thickness in AD mice, alleviated skin damage, reduced mast cell number, diminished IgE, TSLP, IL-4, and IL-13 levels, and peripheral blood Th2 cell content, with no significant changes in IFN-γ level. CQ alleviated type 2 inflammatory response in AD mice by inhibiting the activation of TLR3. CQ suppressed NLRP3 inflammasome activation. Activating TLR3/NLRP3 annulled CQ-mediated alleviation on type 2 inflammatory response in AD mice. Conclusion: CQ alleviated type 2 inflammatory response in AD mice by inhibiting TLR3 activation and NLRP3 inflammasome activation. Keywords: atopic dermatitis, chloroquine, toll-like receptor 3, NLRP3 inflammasome, type 2 inflammation, MC903 Atopic dermatitis (AD) is a common chronic, non-infectious skin disease that arises from the intricate interplay of immunological, genetic, and environmental elements. 1 As a typical type 2 inflammatory disease, AD is characterized by elevated levels of serum immunoglobulin E (IgE), intense itch, recurrent eczematous lesions, epidermal hyperplasia, the generation of inflammatory mediators, and the infiltration of T-cells and dendritic cells (DCs). 2–4 For decades, the incidence rate of AD has been rising steadily, 5 influencing up to 10% of grown-ups, 6 which seriously interferes with the daily activities of the patients and greatly reduces their quality of life. 7 AD may present with distinct clinical phenotypes, leading to challenges in diagnosis. 6 Many countries have a dearth of approved medications for atopic dermatitis. Therefore, it is of great significance to deeply understand the mechanism of AD and search for effective methods for mitigating AD. The excessive type 2 inflammatory response in AD is mainly driven by type 2 helper T cells (Th2) and group 2 innate lymphoid cells (ILC2s). 8,9 MC903 (calcipotriol) is an active vitamin D analogue, 10 which can induce AD-like type 2 skin inflammation in mice by up-regulating thymic stromal-derived lymphopoietin (TSLP) and is widely used to establish AD animal models. 11 Research has shown that TSLP serves as an early promoter of AD, originating from several cellular sources like mast cells and keratinocytes. 11,12 It has the capability to generate type 2 cytokines, including interleukin (IL)-4 and IL-13, which can activate mast cells, enhance IgE expression, and ultimately induce skin inflammation resembling AD. 13,14 Toll-like receptors (TLRs) are a group of receptors crucial for innate immune signaling and inflammatory response triggering, closely linked to the onset and progression of AD. 15 An existing study has found that using the TLR3 agonist polyinosinic:polycytidylic acid [poly (I:C)] to induce TLR3 activation can exacerbate AD-like symptoms in mice induced by MC903. 16 Notably, activation of TLR3, a member of the TLR family, can induce the production and release of TSLP, further exacerbating Th2 inflammatory response. 17 However, the study of TLR3 in AD is still controversial. According to reports, inflammasomes are mult -Abstract Truncated-
dermatology